Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).Bank of America Securities lowered the Adobe target price from $640.00 to $605.00.The main fuel contract rose by 6.00% in the day and is now reported at 3249.00 yuan/ton.
China Chengtong and China Yizhong set up an enterprise management center with a capital contribution of 6.25 billion yuan. According to Tianyancha App, Zhongcheng (Beijing) Enterprise Management Center (Limited Partnership) was recently established. The executive partner is Yizhong Group Sunac Technology Development Co., Ltd., with a capital contribution of 6.25 billion yuan. The business scope is enterprise management and enterprise management consulting. It is owned by China Chengtong's Beijing Chengtong Capital Investment Co., Ltd., China Yizhong Group Co., Ltd. and its subsidiary Sunac Technology Development Co., Ltd.The European Central Bank announced that it would cut three key interest rates in the euro zone. On the 12th local time, the European Central Bank held a monetary policy meeting at its headquarters in Frankfurt, Germany, and decided to cut all three key interest rates by 25 basis points. This is also the fourth time that the European Central Bank cut interest rates this year after it announced a rate cut in June this year. According to the latest interest rate resolution announced by the European Central Bank, the deposit mechanism interest rate is reduced to 3.0%, the main refinancing interest rate is reduced to 3.15%, and the marginal lending interest rate is reduced to 3.40%. (CCTV News)The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)
COMEX silver fell 1% in the day, Comex silver fell 1% in the day, and it is now reported at $32.63 per ounce.Tianyu Bio staged the "Heaven and Earth" market in the afternoon, with a turnover of over 900 million yuan.The Bank of Japan's short-term survey may show that business confidence has hardly changed. It is reported that the short-term survey released by the Bank of Japan on Friday may show that the mood of large manufacturers has remained almost unchanged in the last quarter under the influence of complex signals such as the recovery of the automobile industry and concerns about the global economic slowdown. Economists surveyed by data provider Quick predict that the prosperity judgment index of large-scale manufacturing industry will be +12, compared with +13 in the last survey. The survey is closely watched for clues about the decision of the Bank of Japan at its meeting next week. If it shows strong capital expenditure plan, high inflation expectation and tight employment situation, it may support the idea of raising interest rates early.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13